T
Tenny Mudianto
Researcher at Harvard University
Publications - 13
Citations - 528
Tenny Mudianto is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Head and neck squamous-cell carcinoma. The author has an hindex of 6, co-authored 10 publications receiving 272 citations. Previous affiliations of Tenny Mudianto include Boston University.
Papers
More filters
Journal ArticleDOI
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Ravindra Uppaluri,Ravindra Uppaluri,Katie M. Campbell,Ann Marie Egloff,Paul Zolkind,Zachary L. Skidmore,Brian Nussenbaum,Randal C. Paniello,Jason T. Rich,Ryan S. Jackson,Patrik Pipkorn,Loren S. Michel,Jessica Ley,Peter Oppelt,Gavin P. Dunn,Erica K. Barnell,Nicholas C. Spies,Tianxiang Lin,Tiantian Li,David Mulder,Youstina Hanna,Iulia Cirlan,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Tenny Mudianto,Rachel S. Riley,Liye Zhou,Vickie Y. Jo,Matthew D. Stachler,Glenn J. Hanna,Jason I. Kass,Jason I. Kass,Robert I. Haddad,Robert I. Haddad,Jonathan D. Schoenfeld,Jonathan D. Schoenfeld,Evisa Gjini,Ana Lako,Wade L. Thorstad,Mackenzie Daly,Scott J. Rodig,Ian S. Hagemann,Dorina Kallogjeri,Jay F. Piccirillo,Rebecca D. Chernock,Malachi Griffith,Obi L. Griffith,Douglas Adkins +48 more
TL;DR: Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses, and the 1-year relapse rate in patients with high-risk pathology was lower than historical.
Journal ArticleDOI
Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancer
Liye Zhou,Tenny Mudianto,Xiaojing Ma,Xiaojing Ma,Rachel S. Riley,Ravindra Uppaluri,Ravindra Uppaluri +6 more
TL;DR: Combining EZH2 targeting with anti–PD-1 may increase therapeutic susceptibility in HNSCC, and it is demonstrated that targeting EZh2 enhanced antigen presentation and was able to circumvent anti– PD-1 resistance.
Journal ArticleDOI
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Maria Rusan,Maria Rusan,Maria Rusan,Kapsok Li,Kapsok Li,Yvonne Y. Li,Yvonne Y. Li,Camilla L. Christensen,Brian J. Abraham,Nicholas Kwiatkowski,Nicholas Kwiatkowski,Kevin A. Buczkowski,Bruno Bockorny,Bruno Bockorny,Bruno Bockorny,Ting Chen,Shuai Li,Kevin Rhee,Haikuo Zhang,Wankun Chen,Wankun Chen,Hideki Terai,Tiffany Tavares,Alan L. Leggett,Tianxia Li,Yichen Wang,Tinghu Zhang,Tae-Jung Kim,Tae-Jung Kim,Sook Hee Hong,Neermala Poudel-Neupane,Michael Silkes,Tenny Mudianto,Li Tan,Takeshi Shimamura,Matthew Meyerson,Matthew Meyerson,Adam J. Bass,Adam J. Bass,Adam J. Bass,Hideo Watanabe,Nathanael S. Gray,Richard A. Young,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman,Peter S. Hammerman +46 more
TL;DR: Carugo et al. as discussed by the authors showed that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.
Journal ArticleDOI
Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).
Ravindra Uppaluri,Paul Zolkind,Tianxiang Lin,Brian Nussenbaum,Ryan S. Jackson,Jason T. Rich,Patrik Pipkorn,Randal C. Paniello,Wade L. Thorstad,Loren S. Michel,Tenny Mudianto,Peter John Oppelt,Tanya M. Wildes,Gavin P. Dunn,Jay F. Piccirillo,Dorina Kallogjeri,Scott J. Rodig,Ian S. Hagemann,Rebecca D. Chernock,Douglas Adkins +19 more
TL;DR: Pembrolizumab has efficacy in metastatic HNSCC and treatment intensification in surgically resectable HPV-negative, Stage III/IV H NSCC with neoadjuvant plus post-oception chemotherapy is hypothesized.
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Maria Rusan,Maria Rusan,Maria Rusan,Kapsok Li,Kapsok Li,Yvonne Y. Li,Yvonne Y. Li,Camilla L. Christensen,Brian J. Abraham,Nicholas Kwiatkowski,Nicholas Kwiatkowski,Kevin A. Buczkowski,Bruno Bockorny,Bruno Bockorny,Bruno Bockorny,Ting Chen,Shuai Li,Kevin Rhee,Haikuo Zhang,Wankun Chen,Wankun Chen,Hideki Terai,Tiffany Tavares,Alan L. Leggett,Tianxia Li,Yichen Wang,Tinghu Zhang,Tae-Jung Kim,Tae-Jung Kim,Sook Hee Hong,Neermala Poudel-Neupane,Michael Silkes,Tenny Mudianto,Li Tan,Takeshi Shimamura,Matthew Meyerson,Matthew Meyerson,Adam J. Bass,Adam J. Bass,Adam J. Bass,Hideo Watanabe,Nathanael S. Gray,Richard A. Young,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman,Peter S. Hammerman +46 more
TL;DR: It is shown that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.